Login / Signup

Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.

Steven M KawutChristine L Archer-ChickoAngela DeMicheleJason S FritzJames R KlingerBonnie KyHarold I PalevskyAmy J PalmiscianoMamta PatelDiane PinderKathleen J PropertK Akaya SmithFrank StanczykRussell TracyAnjali VaidyaMary E WhittenhallCorey E Ventetuolo
Published in: American journal of respiratory and critical care medicine (2017)
Anastrozole significantly reduced E2 levels in patients with PAH but had no effect on TAPSE. Anastrozole was safe, well tolerated, and improved 6-minute-walk distance in this small "proof-of-principle" study. Larger and longer phase II clinical trials of anastrozole may be warranted in patients with PAH. Clinical trial registered with www.clinicaltrials.gov (NCT 1545336).
Keyphrases
  • clinical trial
  • phase ii
  • double blind
  • pulmonary arterial hypertension
  • placebo controlled
  • open label
  • phase iii
  • pulmonary artery
  • study protocol
  • pulmonary hypertension
  • polycyclic aromatic hydrocarbons